Pharm-Olam nabs PE investment amid 'market void' for mid-tier CROs

By Melissa Fassbender contact

- Last updated on GMT

Pharm-Olam nabs PE investment amid ‘market void’ for mid-tier CROs

Related tags: Private equity firm, Venture capital

Pharm-Olam has secured an investment from Quad-C Management as the private equity firm eyes add-on acquisitions to complement organic growth.

Frank Winslow, a Partner at Quad-C, told us the Virginia-headquartered middle market private equity firm has been researching and pursuing investments in the CRO space for more than a decade.

During this time the industry has seen “quite a bit of consolidation​,” he said, which has created a “real void in the market for independent, mid-tier CROs​.”

As Outsourcing-Pharma.com previously reported​, outsourcing companies are expected to witness “significant investments​” from private equity and venture capital.

The industry should benefit from tailwinds, as increasing costs for drug makers supports ongoing globalization trends​,” explained Winslow. “The growing complexity of clinical trials also supports a company like Pharm-Olam​.”

The investment marks the company’s first in the CRO industry, though Windlow said the deal fits into the company’s “sweet spot​,” as it looks to bring a business-development mindset and pursue a number of different avenues for growth.

We understand Pharm-Olam's competitive set and see a real opportunity to drive both organic growth and also pursue add-on acquisitions that can add expertise around new verticals or grow the company geographically​,” he added.

The Texas-based CRO currently has 27 offices worldwide though Windlow said Quad-C will expand the company’s reach “to new end markets and new locations​” through strategic transactions.

David Grange of Quad-C will join the Pharm-Olam board as Vice Chairman.

Terms of the transaction were not disclosed.

(Feature image: iStock/pichet_w)

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars